Biotech Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Amenorrhea
Columbia Laboratories Signs U.S. License and Supply Agreement with Ascend Therapeutics to Market PROCHIEVE(R) 4% Progesterone Gel
October 8th, 2007
Columbia Laboratories, Inc. (NASDAQ: CBRX) announced that it has signed an exclusive, five year license and supply agreement with Ascend Therapeutics, Inc., for the Company's PROCHIEVE (R) 4% progesterone gel, currently indicated and FDA-approved for the treatment of secondary amenorrhea (secondary amenorrhea is lack of periods for six or more months in a woman who has already started menstruation and who is not pregnant, lactating, or in menopause). Under terms of the agreement, effective January 1, 2008, Ascend Therapeutics will be responsible for marketing and sales of PROCHIEVE (R) 4% in the United States using its existing 100-person sales force that calls on a...
Source: Biotech Business Week (2007-10-08)
|
